“Big money” Positions

In Q4 2018 Revance Therapeutics (NASDAQ:RVNC) big money sentiment decreased to 1.02, according to SEC.gov filings. So its down -0.45, from 2018Q3’s 1.47. 44 active investment managers increased or started new equity positions, while 43 decreased and sold their holdings in Revance Therapeutics so the sentiment is negative. These funds own 33.24 million shares, that’s up from 32.53 million shares in 2018Q3. Funds holding Revance Therapeutics in top 10 changed to 0 from 0 for the same number . 18 Investors Sold All; 25 Reduced Holdings; 31 increased stakes while 13 active investment managers bought stakes.

Significant Revance Therapeutics Investors

As of Q4 2018 Sio Capital Management Llc has 1.23% invested in Revance Therapeutics. Revance Therapeutics’s shareholder Fosun International Ltd owns 472,532 shares as of Q4 2018. Arrowmark Colorado Holdings Llc reported 2.31 million shares. The Sweden-based fund Rhenman & Partners Asset Management Ab have invested about 0.44% of the investment professional’s stock portfolio in Revance Therapeutics. The New York-based fund Quinn Opportunity Partners Llc looks positive on Revance Therapeutics, having 56,672 shares.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications.The firm is valued at $688.61 million. The company's lead drug candidate is DaxibotulinumtoxinA for injection , which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.Currently it has negative earnings. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development.

RVNC hit $15.64 during the last trading session after $0.24 change.Currently Revance Therapeutics, Inc. is downtrending after 42.41% change in last March 27, 2018. RVNC has 231,945 shares volume. RVNC underperformed by 46.78% the S&P500.

Revance Therapeutics, Inc. (NASDAQ:RVNC)’s earnings report is awaited on May, 14., RTT reports. Analysts forecast $-0.83 EPS. That’s $0.14 up or 14.43 % from 2018’s earnings of $-0.97. Wall Street sees -25.89 % EPS growth as of May, 14.

10,451 are owned by Gsa Ptnrs Llp. Commercial Bank Of Ny Mellon Corp owns 2.54M shs or 0.02% of their US capital. Captrust Fincl Advsr holds 0% or 200 shs in its capital. New York State Common Retirement Fund reported 31,500 shs. Parametric Portfolio Assocs Ltd Liability Corporation reported 0% stake. 20,000 were accumulated by Hightower Limited. Glenmede Company Na reported 110 shs. Nottingham Advisors Inc holds 11,312 shs. Morgan Stanley stated it has 153,246 shs. Citigroup invested in 20,108 shs or 0% of the stock. 48 are held by Pnc Service Gp. Moreover, Voya Inv Mgmt Ltd Liability Company has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 13,606 shs. Charles Schwab Invest Mngmt reported 177,028 shs. Rhumbline Advisers accumulated 43,339 shs. California Pub Employees Retirement System has 51,755 shs for 0% of their capital.

Revance Therapeutics, Inc. registered $80,454 net activity with 0 insider buys and 4 selling transactions since November 9, 2018.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Ratings Coverage

Total analysts of 6 have positions in Revance Therapeutics (NASDAQ:RVNC) as follows: 5 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 83%. The firm has $55 highest while $25 is the lowest target price. The average target $41.60 is 165.98% above the last ($15.64) price. Since November 16, 2018 according to StockzIntelligence Inc Revance Therapeutics has 7 analyst reports. On Tuesday, February 26 the stock has “Buy” rating by Cowen & Co. On Thursday, February 28 H.C. Wainwright maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) rating. H.C. Wainwright has “Buy” rating and $25 target. On Wednesday, February 27 the rating was maintained by Mizuho with “Buy”. On Friday, February 15 the firm earned “Hold” rating by Wells Fargo. On Friday, November 16 the company was upgraded by Guggenheim.

For more Revance Therapeutics, Inc. (NASDAQ:RVNC) news released recently go to: Seekingalpha.com, Benzinga.com, Seekingalpha.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Revance readies stock offering – Seeking Alpha” released on January 15, 2019, “JMP: Changing Competitive Landscape Makes Revance (NYSE:AGN) Less Appealing – Benzinga” on September 17, 2018, “Revance Therapeutics: New Data And Partnership A Welcome Development – Seeking Alpha” with a publish date: December 05, 2018, “Revance on recent regulatory progress and provides anticipated 2019 milestones – Seeking Alpha” and the last “Health Care Sector Update for 12/04/2018: NVLN, RVNC, ARDS – Nasdaq” with publication date: December 04, 2018.